Summary
Gepirone (BMY 13805), a buspirone analog, was used to determine the antianxiety mechanism of the arylpiperazine class of drugs. Because of the weak effects of these drugs on conflict behavior, isolation-induced aggressive mice were used as the antianxiety model. Gepirone, like buspirone, potently inhibited attacks against group housed intruder mice (ED50 = 4.5 mg/kg i. p.) without causing sedation or ataxia. Inhibition of aggression was potentiated by co-administration of 0.25 mg/kg methiothepin or 2.5 mg/kg methysergide. Gepirone had variable effects on dopamine metabolism and reduced 5-hydroxytryptamine (5HT) metabolism about one third after a dose of 2.5 mg/kg. In contrast to buspirone, which markedly increased dopaminergic impulse flow, gepirone inhibited the firing of most cells recorded from the substantia nigra zona compacta in doses of 2.3–10 mg/kg i. v. and the effects were reversible by administration of haloperidol. The common metabolite of buspirone and gepirone, 1-(2-pyrimidinyl)-piperazine, caused increased firing rates only. Gepirone potently inhibited serotonergic impulse flow recorded from the dorsal raphe nucleus (88.3% after 0.04 mg/kg) and this effect was partially reversed by serotonergic antagonists. Both buspirone and gepirone displaced [3H]-5HT from the 5HT1a binding site in the hippocampus with IC50 values of 10 and 58 nM, respectively. Non-alkyl substituted aryl-piperazines displaced [3H]-5HT from both 5HT1a and 5HT1b binding sites. Thus, although gepirone may be a weak postsynaptic 5HT agonist, its primary effect is to decrease 5HT neurotransmission. In support of this conclusion was the observed potentiation of antiaggressive effects by blocking 5HT receptors wit small doses of methiothepin or methysergide, which would exacerbate the decreased release of 5HT caused by gepirone. These results are in harmony with reports that decreased serotonergic activity has anxiolytic-like effects in animal models of anxiety.
Similar content being viewed by others
References
Aghajanian GK, Wang RY (1978) Physiology and pharmacology of central serotonergic neurons. In: Lipton MS (ed) Psychopharmacology: A generation of progress. Raven Press, New York, pp 171–183
Andrade R, Nicoll RA (1985) The novel anxiolytic buspirone elicits a small hyperpolerization and reduced serotonin responses at putative 5-HT1 receptors on hippocampal CA1 pyramidal cells. Soc Neurosci Abstr 11:597
Bannon MM, Michaud RL, Roth RH (1981) Mesocortical dopamine neurons: lack of autoreceptors modulating dopamine synthesis. Mol Pharmacol 19:270–275
Barlow RB (1983) Biodata handling with microcomputers. Elsevier Science Publishers, London
Bunney BS, Walters JR, Roth RH, Aghajanian GK (1973) Dopaminergic neurons: Effect of antipsychotic drugs and amphetamine on single cell activity. J Pharmacol Exp Ther 185:650–671
Caccia S, Garattini S, Mancinelli A, Muglia M (1982) Identification and quantification of 1-(2-pyrimidinyl)piperazine, an active metabolite of the anxiolytic agent buspirone, in rat plasma and brain. J Chromatog 252:310–314
Carter CJ, Pycock CJ (1978) A study of the sites of interaction between dopamine and 5-hydroxytryptamine for the production of fluphenazine-induced catalepsy. Naunyn-Schmiedeberg's Arch Pharmacol 304:135–139
Cimino M, Ponzio F, Achilli G, Vantini G, Perego C, Algeri S, Garattini S (1983) Dopaminergic effects of buspirone, a novel anxiolytic agent. Biochem Pharmacol 32:1069–1074
Cott JM, Kurtz NM, Robinson DS (1985) Gepirone (BMY 13805): A new analog of buspirone with anxiolytic potential. IVth World Congr Biol Psychiatr Abst, p 213
DaVanzo JP (1969) Observations related to drug-induced alterations in aggressive behaviour. In: Garattini E, Sigg B (eds) Aggressive behaviour. Excerpta Medica, Amsterdam, pp 263–272
DaVanzo JP, Daugherty M, Ruckart R, Kang L (1966) Pharmacological and biochemical studies in isolation-induced fighting mice. Psychopharmacology (Berlin) 9:210–219
DeMontigny C, Blier P, Chaput Y (1984) Electrophysiologically-identified serotonin receptors in the rat CNS. Neuropharmacology 23:1511–1520
Dompert WU, Glaser T, Traber J (1985) 3H-TVX Q 7821: Identification of 5HT1 binding sites as target for a novel putative anxiolytic. Naunyn-Schmiedeberg's Arch Pharmacol 328:467–470
Eison AS, Eison MS, Riblet LA, Temple DL (1983a) Indications of serotonergic involvement in the actions of a potential nonbenzodiazepine anxiolytic: MJ 13805. Soc Neurosci Abstr 9:436
Eison MS, VanderMaelen CP, Matheson GK, Eison AS, Taylor DP (1983b) Interactions of the anxioselective agent buspirone with central serotonin systems. Soc Neurosci Abstr 9:435
Farber J, Miller JD, Crawford KA, McMillen BA (1983) Dopamine metabolism and receptor sensitivity in rat brain after REM sleep deprivation. Pharmacol Biochem Behav 18:509–513
Gammans RE, Mayol RF, Eison MS (1983) Concentration of buspirone and 1-pyrimidinylperazine, a metabolite, in rat brain. Fed Proc 42:377
Gehlbach G, VanderMaelen CP (1985) The nonbenzodiazepine antidepressant-anxiolytic candidate, gepirone, inhibits serotonergic dorsal raphe neurons in the rat brain slice. Soc Neurosci Abstr 11:186
German DC, Harden, H, Sanghera MK, Mann D, Kiser RS, Miller HH, Shore PA (1979) Doparninergic neuronal responses to a non-amphetamine CNS stimulant. J Neural Trans 44:39–49
Glaser T, Traber J (1983) Buspirone: Action on serotonin receptors in calf hippocampus. Eur J Pharmacol 88:137–138
Glowinski J, Iversen LL (1966) Regional studies of catecholamines in rat brain. J Neurochem 13:655–669
Goldberg HL, Finnerty RJ (1979) The comparative efficacy of buspirone or diazepam in the treatment of anxiety. Am J Psychiatr 19:270–275
Hjorth S, Carlsson A (1982) Buspirone: effects on central monoaminergic neurotransmission-possible relevance to animal experimental and clinical findings. Eur J Pharmacol 83:298–303
Hjorth S, Carlsson A, Lindberg P, Sanchez D, Wikstrom H, Arvidsson L-E, Hacksell U, Nilsson JLG (1982) 8-Hydroxy-2(di-n-propyl-amino)tetralin, 8-OH-DPAT, a potent and selective simplified ergot congener with central 5-HT-receptor stimulating activity. J Neural Transm 55:169–188
Iversen SD (1984) 5-HT and anxiety. Neuropharmacology 23:1553–1560
Kaulen P, Brunig G, Schneider U, Baumgarten HG (1985) Autoradiographic localization of [3H]buspirone binding sites in rat brain. Neurosci Lett 53:191–195
Konig JFR, Klippel RA (1963) The rat brain: A stereotaxic atlas. R. E. Krieger Publishing Co., New York
Litchfeld JT, Wilcoxon F (1949) A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96:99–113
Marcinkiewicz M, Verge D, Gozlan H, Pichat L, Hamon M (1984) Autoradiographic evidence for the heterogeneity of 5-HT, sites in the rat brain. Brain Res 291:159–163
McMillen BA (1985) Acute and subchronic effects of MJ 13859, a potential antipsychotic drug, on rat brain dopaminergic function. J Pharmacol Exp Ther 233:369–375
McMillen BA (1986) Buspirone and the dopaminergic system. In: Tunnicliff G, Eison AS, Taylor DP (eds) Buspirone: Mechanisms and clinical aspects. Academic Press, New York (in press)
McMillen BA, Matthews RT, Sanghera MK, Shepard PD, German DC (1983) Dopamine receptor antagonism by the novel antianxiety drug, buspirone. J Neurosci 3:733–738
McMillen BA, Mattiace LA (1983) Comparative neuropharmacology of buspirone and MJ 13805, a potential anti-anxiety drug. J Neural Transm 57:255–265
McMillen BA, McDonald CC (1983) Selective effects of buspirone and molindone on dopamine metabolism and function in the rat. Neuropharmacology 22:273–278
Miczek KA (1974) Intraspecies aggression in rats: Effects of d-amphetamine and chlordiazepoxide. Psychopharmacology 39:275–301
Moskowitz H, Smiley A (1982) Effects of chronically administered buspirone and diazepam on driving-related skills performance. J Clin Psychiatr 43 (Sec.2):45–55
Nelson DL, Herbert A, Bourgoni S, Glowinski J, Hamon M (1978) Characteristics of central 5-HT receptors and their adaptive changes following intracerebral 5,7-dihydroxytryptamine administration in the rat. Mol Pharmacol 14:983–995
Olivier B, Van Aken M, Jaarsma I, Van Corschot R, Zethof T, Bradford D (1984) Behavioral effects of psychoactive drugs on agonistic behavior of male territorial rats (resident-intruder model). Prog Clin Biol Res 167:137–156
Pazos A, Palacios JM (1985) Quantitative autoradiographic map** of serotonin receptors in the rat brain. I. serotonin-1 receptors. Brain Res 346:205–230
Peroutka SJ (1985) Selective labeling 5-HT1a and 5-HT1b binding sites in bovine brain. Brain Res 344:167–171
Peroutka SJ, Ison PJ, Schlegel JR (1985) Direct labeling of 5-HT1a and 5-HT1b binding sites with 3H-OH-DPAT and 3H-5HT in bovine brain. Soc Neurosci Abstr 11:1257
Rebec GV, Cartis SD, Zimmermann KS (1982) Dorsal raphe neurons: self-inhibition by an amphetamine-induced release of endogenous serotonin. Brain Res 251:374–379
Riblet LA, Taylor DP, Eison MS, Stanton HC (1982) Pharmacology and neurochemistry of buspirone. J Clin Psychiat 43 (Sect. 2):11–16
Rickels K, Weisman K, Norstad N, Singer M, Stoltz D, Brown A, Danton J (1982) Buspirone and diazepam in anxiety: A controlled study. J Clin Psychiat 43 (Sect. 2), 81–86
Sanghera MK, German DC (1983) The effects of benzodiazepine and nonbenzodiazepine anxiolytics on locus coeruleus activity. J Neural Transm 57:267–279
Taylor DP, Gammons RE, Hyslop KK, Matheson GK, Mayol RF, Moon-Edley S (1984) Regional localization of the anxioselective drug buspirone in rat brain. Soc Neurosci Abstr 10:17
Thiebot MH, Hamon M, Soubrie P (1982) Attenuation of induced-anxiety in rats by chlordiazepoxide: Role of raphe dorsalis benzodiazepine binding sites and serotonergic neurons. Neurosci 7:2287–2294
Thiebot M-H Soubrie P, Hamon M, Simon P (1984) Evidence against the involvement of serotonergic neurons in the antipunishment activity of diazepam in the rat. Psychopharmacology 82:355–359
Trulson ME, Howell GA, Brandstetter JW, Frederickson MH, Frederickson CJ (1982) In vitro recording of raphe unit activity: Evidence for endogenous rhythms in presumed serotonergic neurons. Life Sci 31:785–790
Tye NC, Iversen SD, Green AR (1979) The effects of benzodiazepines and serotonergic manipulations on punished responding. Neuropharmacology 18:689–695
VanderMaelen CP, Wilderman RC (1984) Buspirone, a nonbenzodiazepine anxiolytic drug, causes inhibition of serotonergic dorsal raphe neurons in the rat brain slice. Soc Neurosci Abstr 10:259
Wang RY, Aghajanian GK (1977) Antidromically identified serotonergic neurons in the rat midbrain raphe: Evidence for collateral inhibition. Brain Res 132:186–193
Weissman BA, Barrett JE, Brady LS, Witkin JM, Mendelson WB, Paul SM, Skolnick P (1984) Behavioral and Neurochemical studies on the anticonflict actions of buspirone. Drug Develop Res 4:83–93
Witkin JM, Barrett JE (1985) Interaction of buspirone and dopaminergic agents on punished behavior of pigeons. Pharmacol Biochem Behav 24:751–756
Wood PL, Nair NPV, Lal S, Etienne P (1983) Buspirone: A potential atypical neuroleptic. Life Sci 33:269–273
Yocca FD, Maayani S (1985) Actions of gepirone (BMY 13805) on functional 5-HT receptors. Pharmacologist 27:78
Zar JH (1984) Biostatistical analysis. Prentice-Hall, Inc., Englewood Cliffs, NJ
Author information
Authors and Affiliations
Additional information
Portions of this work were presented at the IVth World Congress of Biological Psychiatry, September, 1985 in Philadelphia
Send offprint requests to B. A. McMillen at the above address
Rights and permissions
About this article
Cite this article
McMillen, B.A., Scott, S.M., Williams, H.L. et al. Effects of gepirone, an aryl-piperazine anxiolytic drug, on aggressive behavior and brain monoaminergic neurotransmission. Naunyn-Schmiedeberg's Arch Pharmacol 335, 454–464 (1987). https://doi.org/10.1007/BF00165563
Issue Date:
DOI: https://doi.org/10.1007/BF00165563